[Federal Register Volume 65, Number 166 (Friday, August 25, 2000)]
[Notices]
[Page 51832]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-21719]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Clinical Laboratory Improvement Advisory Committee (CLIAC): 
Meeting

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the following committee meetings.
    Name: Clinical Laboratory Improvement Advisory Committee 
(CLIAC).
    Times and Dates: 8:30 a.m.-5 p.m., September 27, 2000, 8:30 
a.m.-3:30 p.m., September 28, 2000.
    Place: CDC, Koger Center, Williams Building, Conference Rooms 
1802 and 1805, 2877 Brandywine Road, Atlanta, Georgia 30341.
    Status: Open to the public, limited only by the space available. 
The meeting room accommodates approximately 85 people.
    Purpose: This committee is charged with providing scientific and 
technical advice and guidance to the Secretary of Health and Human 
Services, the Assistant Secretary for Health, and the Director, CDC, 
regarding the need for, and the nature of, revisions to the 
standards under which clinical laboratories are regulated; the 
impact of proposed revisions to the standards; and the modification 
of the standards to accommodate technological advances.
    Matters to be Discussed: The morning session of the first day 
will be devoted to orientation of new members. The orientation is 
background information on the process for new committee members. 
Although members of the public may attend, the orientation is not 
part of the public meeting. The agenda will include an orientation 
of new members, workgroup report on specimens and test systems not 
currently regulated under Clinical Laboratory Improvement Amendments 
(CLIA), and updates from CDC, Food and Drug Administration and 
Health Care Financing Administration.
    The Committee solicits oral and written testimony on specimens 
and test systems not currently regulated under CLIA. Requests to 
make an oral presentation should be submitted in writing to the 
contact person listed below by close of business, September 20, 
2000. All requests to make oral comments should contain the name, 
address, telephone number, and organizational affiliation of the 
presenter.
    Written comments should not exceed five single-spaced typed 
pages in length and should be received by the contact person listed 
below by close of business, September 20, 2000.
    Agenda items are subject to change as priorities dictate.
    Contact Person for Additional Information:  Rhonda Whalen, 
Acting Chief, Laboratory Practice Standards Branch, Division of 
Laboratory Systems, Public Health Practice Program Office, CDC, 4770 
Buford Highway, NE, Mailstop F-11, Atlanta, Georgia 30341-3724, 
telephone 770/488-8042, fax 770/488-8279.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining 
to announcements of meetings and other committee management 
activities for both CDC and the Agency for Toxic Substances and 
Disease Registry.

    Dated: August 18, 2000.
Carolyn J. Russell,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. 00-21719 Filed 8-24-00; 8:45 am]
BILLING CODE 4163-18-P